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682Drug-coated balloon angioplasty after directional
atherectomy improves outcome in restenotic
femoropopliteal arteries
Sebastian Sixt, MD,a,b Oscar Gerardo Carpio Cancino, MD,a András Treszl, MD,c Ulrich Beschorner, MD,a
Roland Macharzina, MD,a Aljoscha Rastan, MD,a Hans Krankenberg, MD,b Franz-Josef Neumann, MD,a
and Thomas Zeller, MD,a Bad Krozingen and Hamburg, Germany
Background: Restenosis remains an unresolved problem despite different treatment modalities and new stent technology
in femoropopliteal arteries. No standard therapy has proven to provide acceptable outcome data for this entity. Direc-
tional atherectomy alone did not result in satisfactory long-term patency rates. The outcome might be improved in
conjunction with drug-coated balloon angioplasty.
Methods: In this retrospective study, restenotic lesions of the femoropopliteal arteries were treated with directed athe-
rectomy in 89 lesions of consecutive patients (58% male; mean age, 69 ± 11 years). All patients received adjunctive
treatment with conventional balloon percutaneous angioplasty (PTA; n[ 60) or drug-coated balloon angioplasty (DCB;
n [ 29).
Results: Lesion location was in the stent (DCB [n[ 27] vs PTA [n[ 36]) and in native restenotic vessels (DCB [n[ 2]
vs PTA [n [ 25]). The 1-year Kaplan-Meier freedom from restenosis estimates (95% conﬁdence intervals) in the DCB
and PTA groups were 84.7% (70.9%-98.5%) and 43.8% (30.5%-57.1%), respectively. In a multivariable Cox model for
restenosis, DCB treatment had a hazard ratio (95% conﬁdence interval) of 0.28 (0.12-0.66; P [ .0036) compared with
the PTA group. In the multivariable model for procedural success, the effect of treatment did not differ between PTA and
DCB (P [ .134).
Conclusions: The combination of directed atherectomy with adjunctive DCB is associated with a better event-free survival
at 12 months of follow-up compared with PTA after directed atherectomy. (J Vasc Surg 2013;58:682-6.)The more liberal use of endovascular treatment for
peripheral artery occlusive disease is aligned with an over-
whelming and still unresolved problem of restenosis. It is
a matter of debate whether stent-supported angioplasty
has any positive impact on technical and clinical outcomes.1
Particularly in longer femoropopliteal artery lesions, reste-
nosis is high and exceeds 50% after plain balloon angio-
plasty alone.2 Improved outcomes were reported after
stent-supported angioplasty with newer-generation nitinol
stents.2 Nevertheless, restenosis, regardless of whether in-
stent or in the native vessel, remains an unresolved
problem.
Plain balloon angioplasty, cutting-balloon angioplasty,
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(DA) resulted in 1-year patency rates of w50%.5 Recent
reports about drug-eluting technologies in peripheral
arteries resulted in conﬂicting and discrepant outcomes.6-8
Positive data were referred to drug (paclitaxel)-coated
balloons (DCB) and paclitaxel-releasing stents in femor-
opopliteal arteries.6,9 Favorable results were also reported
in small coronary arteries for treatment of in-stent resteno-
sis.10 Our goal in this study was to investigate the effect of
DCB as an adjunct to DA in restenotic femoropopliteal
lesions on time of being free from restenosis.
METHODS
This study was approved by the local Investigational
Review Board.
Patients. This retrospective analysis of a prospective
register for treatment of restenosis included consecutive
patients with femoropopliteal occlusive disease treated
with DA. Between June 2002 and December 2009,
patients were treated as an adjunct to DA, with conven-
tional balloon percutaneous angioplasty (PTA) or between
April and December 2009 with DCB. Aside from one
patient, Rutherford classiﬁcation (2 to 5) was applicable.
Devices. SilverHawk (Covedian-ev3, Dublin, Ireland)
devices were used (LS and LX) exclusively. Stenting was
discouraged and only allowed in bailout situations such as
in instances of ﬂow-limiting dissection or in the presence
of residual stenosis ($30%) after atherectomy and low-
pressure angioplasty. Angiographic parameters, including
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target lesion length, were rated by an experienced inter-
ventionalist based on visual estimation using a radiopaque
ruler or by on-table quantitative angiography (Angiostar
and Multistar, Siemens, Erlangen, Germany). Pre-
intervention and postintervention angiograms were done
to document vessel runoff and to assess embolization
before and after the procedure.
Follow-up assessment. All patients were scheduled
for complete follow-up examinations at discharge, at 6
and 12 months, and every year thereafter, including clinical
history, physical examination, and noninvasive measure-
ments with Doppler occlusive pressure, with calculation of
the ankle-brachial index (ABI), and color duplex ultra-
sound imaging. The deﬁnition of relevant restenosis
($50%) was based on duplex ultrasound assessment,
deﬁned as a proximal systolic peak ﬂow velocity ratio $2.4.
Changes in the clinical status within the ﬁrst 12 months
were assessed according the recommended standards.11
Medications. Antiplatelet therapy was started at the
latest the day before the intervention with a 600-mg
loading dose of clopidogrel and 500 mg of acetylsalicylic
acid. Postinterventional therapy consisted of acetylsalicylic
acid (100 mg/d) for life and clopidogrel (75 mg/d) for 4
weeks. After sheath placement, heparin (5000 IU) was
given intra-arterially.
Deﬁnition of end points. Technical success after
atherectomy alone was deﬁned as residual stenosis of
#50%; however, procedural success was deﬁned as #30%
residual stenosis. Both were evaluated at the end of the
procedure. Event-free survival was deﬁned as the time to
the detection of restenosis.
Statistical analysis. Baseline patient and lesion-speciﬁc
characteristics according to treatment groups are expressed
as absolute numbers (percentages) or mean (standard
deviation). Variables between treatment groups were
compared using the Fisher exact test for categoric data and
the Student t-test for continuous data. We also calculated
standardized differences (ie, difference in means or
proportions divided by pooled standard deviation) to
characterize baseline imbalance between treatment groups.
Standardized differences exceeding an absolute value of
0.2 were considered large.
Because this was an observational study and patients
were not randomized to treatment groups, we aimed to
control for selection bias when evaluating the effect of
treatment. Therefore, as a ﬁrst step, we performed logistic
regression with backward selection using all variables from
Tables I and II having an absolute value of standardized
difference between treatment groups >.200 (with a liberal
P value of staying in the model of P ¼ .5). Propensity
scores (ie, the conditional probability of each patient
receiving PTA or DCB treatment) were calculated from
the following variables: kidney failure, angiotensin-
enzyme converting inhibitor/angiotensin receptor blocker,
side, superﬁcial femoral artery, vessel runoff, stenosis after
atherectomy, ﬁnal stenosis, and ﬁnal minimal lumen diam-
eter (MLD).In the second step, inverse propensity weighting12 was
applied to adjust for confounding when comparing treat-
ment groups on outcome in all multivariable models
described below. An important factor, the year of surgery
between the two treatment groups was unbalanced; there-
fore, this variable was always considered as a covariate in
multivariable models. A Cox proportional hazard regres-
sion model was used to calculate hazard ratios. Baseline-
adjusted analysis of covariance was applied to estimate
changes after 1 year of follow-up for ABI. Logistic regres-
sion was calculated to quantify procedural success and
improvement according to the Rutherford scale between
treatment groups after 1 year of follow-up.
Only the ﬁrst 24 months of the individual patient’s
follow-up period were analyzed. Kaplan-Meier estimates
of being free from restenosis according to treatment group
were calculated.
Nominal P values are reported. Two-tailed P values
<.05 were considered statistically signiﬁcant. Statistical
analyses were performed using SAS 9.2 software (SAS Insti-
tute, Cary, NC) and with the stddiff SAS.13
RESULTS
In this prospective study of 89 patents, 60 were treated
with PTA and 29 with DCB in addition to DA. Lesion
location was in-stent in 27 (30%) or in native restenotic
vessels in two (2%) for the DCB cohort and in-stent in
36 (40%) or in native arteries in 24 (30%) for PTA. Patient
baseline characteristics are reported in Table I. Standard-
ized differences exceeding an absolute value of 0.2 were
considered large.
Acute technical and clinical outcome. The overall
procedural success was 100% in both treatment groups.
Technical success was achieved in 82 patients (92%),
without a signiﬁcant difference between the groups (P ¼
.056). The technical data are reported in Table II.
The mean percentage diameter stenosis for the PTA
and DCB groups was 90%6 9% and 90%6 7%, respectively;
with an average MLD of 0.76 0.6 and 0.66 0.5 mm. The
mean angiographic proximal reference vessel diameter
differed between the PTA and the DCB group (5.5 6 0.8
vs 5.06 0.9;P¼ .013). After atherectomy alone, the residual
stenosis was higher in the PTA group (37% 6 18%) than in
the DCB group (28% 6 11%; P ¼ .004). Additional low-
pressure balloon angioplasty (DCB or PTA) or stenting
(n ¼ 11) led to a ﬁnal residual stenosis of 9% 6 12% in the
PTA group and 14%6 7% in the DCB group (P ¼ .013).
Additional stenting was performed in similar rates in
both cohorts. As a bailout procedure, stent implantation
was indicated in one patient with a type C dissection after
dilatation; in another patient, an already preinterventionally
detected stent fracture in a previously implanted stent led
to stent-in-stent placement. In the remaining nine patients,
residual stenoses of >50% after additional PTA, caused by
heavy or eccentric calciﬁcation, prompted stent implanta-
tion. The increase in MLD after DA was similar between
the two treatment groups (3.8 6 1.2 vs 3.6 6 0.7 mm;
P ¼ .409). After adjunctive procedures, the ﬁnal MLD
Table I. Patient baseline characteristics
Variablesa Entire cohort (n ¼ 89) PTA (n ¼ 60) DCB (n ¼ 29) Standardized differenceb P
Male 52 (58) 37 (62) 15 (52) 0.202 .492
Age, years 69 6 11 68 6 10 70 6 13 0.178 .409
Diabetes mellitus type 2 40 (45) 26 (43) 14 (48) 0.099 .820
Arterial hypertension 79 (89) 55 (92) 24 (83) 0.269 .284
Hypercholesterolemia 76 (85) 55 (92) 21 (72) 0.518 .024
Smoker 52 (58) 38 (63) 14 (48) 0.307 .251
Family history 15 (17) 15 (25) 0 0.816 .002
Renal insufﬁciency 34 (38) 19 (32) 15 (52) 0.415 .102
Coronary artery disease 7 (8) 7 (12) 0 0.514 .091
Stroke 6 (7) 4 (7) 2 (7) 0.009 >.99
Medication
Aspirin, 100 mg 81 (91) 54 (90) 27 (93) 0.112 >.99
Clopidogrel 84 (94) 56 (93) 28 (97) 0.147 >.99
Oral anticoagulation 20 (22) 13 (22) 7 (24) 0.059 .792
b-blocker 56 (63) 40 (67) 16 (55) 0.237 .352
ACE inhibitor/ARB 61 (69) 44 (73) 17 (59) 0.314 .223
Calcium channel blocker 26 (29) 19 (32) 7 (24) 0.168 .620
Statin 76 (85) 48 (80) 28 (97) 0.532 .053
Diuretic 50 (56) 34 (57) 16 (55) 0.030 >.99
Rutherford category 0.700 .126
2 20 (21) 15 (25) 5 (18)
3 47 (53) 35 (58) 12 (43)
4 9 (10) 5 (8) 4 (14)
5 12 (14) 5 (8) 7 (25)
Ankle-brachial index 0.43 6 0.26 0.44 6 0.26 0.42 6 0.26 0.067 .785
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DCB, drug-coated balloon; PTA, balloon percutaneous angioplasty.
aContinuous data are presented as means 6 standard deviation; categoric data are given as frequency (percentages).
bDifference in means or proportions divided by standard error.
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(5.1 vs 4.4 mm; P < .001).
At discharge, the ABI improved in the total cohort
(P < .001), with no difference in both subcohorts.
Long-term technical and clinical outcome. The
1-year Kaplan-Meier estimates of freedom from restenosis
(95% conﬁdence intervals) in the DCB and PTA groups
were 84.7% (70.9%-98.5%) and 43.8% (30.5%-57.1%),
respectively (Fig).
To adjust for confounding due to imbalanced baseline
variables between the two treatment groups, we applied in-
verse propensity score weighting; moreover, every model
was adjusted for the year of surgery. In the multivariable
Cox model for restenosis, DCB treatment had a hazard
ratio of 0.28 (95% conﬁdence interval, 0.12-0.66; P ¼
.0036) compared with the PTA group. In the multivariable
model for procedural success, the effect of treatment did
not differ between PTA and DCB (P ¼ .134). There was
no difference between baseline-adjusted ABI values after
1 year of follow-up between treatment groups (P ¼ .322).
There was also no difference between the treatment groups
regarding improvement in clinical status (P ¼ .253).
Surgical interventions. Nine patients underwent
bypass surgery during the study follow-up, comprising
a femorocrural bypass in one patient and a femoropopliteal
bypass in eight patients. One patient underwent a supra-
condylar amputation. One patient required a minor
amputation (second toe) because of already preinterven-
tionally existing gangrene.Complications. Two device-related complications
(3.3%), documented as perforation at the treatment site,
occurred in the PTA cohort. Prolonged balloon angioplas-
ty controlled the bleeding in both patients. In one patient
(1.6%), a lesion developed an aneurysm, which was detected
4 months after the intervention. Peripheral embolism
occurred during seven interventions (11.7%); however, all
visible emboli could be aspirated with an aspiration catheter.
Two patients (3.3%) sustained complications related to the
Angio-Seal Vascular Closure device (St. Jude, St. Paul,
Minn) associated with stenosis at the puncture site. A false
aneurysm was detected in two patients (3.3%), of which one
occluded after manual ultrasound-guided compression, and
one required surgical intervention.
In the DCB cohort, peripheral embolism was detected
in ﬁve patients (19%) and was also managed with manual
aspiration. Furthermore, one patient (3.5%) required a rein-
tervention with covered stenting at the puncture site
because of persisting bleeding.
DISCUSSION
The aim of this study was to assess the effect of DCB
angioplasty as an adjunct to DA in restenotic femoropop-
liteal arteries. The results showed that restenosis rates were
higher in the conventional PTA group than in patients
treated with DCB. The mean lesion length was 171 6 124
cm, not different between both subgroups, representing
the real world in daily practice. Despite the tremendous
burden of restenosis related to femoropopliteal intervention,
Table II. Lesion-speciﬁc baseline characteristics
Variablea Entire cohort (n ¼ 89) PTA (n ¼ 60) DCB (n ¼ 29) Standardized differenceb P
Right side 42 (47) 27 (45) 15 (52) 0.135 .652
Common femoral artery 6 (7) 3 (5) 3 (10) 0.202 .387
Deep femoral artery 3 (3) 3 (5) 0 0.324 .548
Superﬁcial femoral artery 73 (82) 52 (87) 21 (72) 0.359 .141
Popliteal artery 45 (51) 32 (53) 13 (45) 0.171 .503
TASC classiﬁcation 0.262 .808
A 12 (14) 7 (12) 5 (19)
B 26 (30) 18 (30) 8 (30)
C 43 (49) 30 (50) 13 (48)
D 6 (7) 5 (8) 1 (4)
Reference vessel diameter, mm 5.3 6 0.8 5.5 6 0.8 5.0 6 0.9 0.555 .013
Lesion length, mm 171 6 124 180 6 136 153 6 93 0.232 .276
Atherectomy passes 11 6 6 10 6 5 13 6 7 0.431 .094
Vessel runoff 0.458 .132
1 vessel 30 (33) 16 (27) 14 (48)
2 vessels 39 (43) 29 (48) 10 (34)
3 vessels 20 (22) 15 (25) 5 (17)
Additional stenting 11 (12) 8 (13) 3 (10) 0.093 >.99
Stenosis, %
Baseline 90 6 8 90 6 9 90 6 7 0.012 .967
After atherectomy 34 6 17 37 6 18 28 6 11 0.613 .004
Final 11 6 11 9 6 12 14 6 7 0.516 .013
Mean luminal diameter, mm
Baseline 0.7 6 0.6 0.7 6 0.7 0.6 6 0.5 0.191 .424
After atherectomy 3.7 6 1.1 3.8 6 1.2 3.6 6 0.7 0.170 .409
Final 4.9 6 1.0 5.1 6 0.9 4.4 6 0.8 0.856 <.001
DCB, Drug-coated balloon; PTA, balloon percutaneous angioplasty; TASC, TransAtlantic Inter-Society Consensus.
aContinuous data are presented as means 6 standard deviation; categoric data are given as frequency (percentages).
bDifference in means or proportions divided by standard error.
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center randomized pilot trial with a small sample size of 40
patients, neither conventional PTA nor cutting-balloon
angioplasty was able to provide acceptable short-term results
for in-stent restenotic lesions of 806 68mm length.3 Reste-
nosis rates at 6monthswere 65% vs 73% (P¼ .73) comparing
cutting-balloon angioplasty with PTA.3 Cryoplasty for in-
stent restenosis resulted in even worse outcome data, with
a 100% failure rate at 12 months.4
A single-center analysis evaluated DA in femoropopli-
teal arteries with de novo and as well restenotic lesions,
including those with in-stent restenosis. The overall tech-
nical and clinical outcome in this cohort was acceptable,
even in long lesions during long-term follow-up, published
just recently (TransAtlantic Inter-Society Consensus C).14
The 12-month data in an earlier analysis revealed the
same technical outcome for restenotic native and in-stent
restenotic target lesions, both with a primary patency rate
of 54%, respectively, which was clearly inferior compared
with de novo lesions with a primary patency rate of 84%.5
However, the lesion length of de novo lesions was signiﬁ-
cantly shorter (43 6 54 mm) compared with restenotic
native (105 6 122 mm) and in-stent restenotic (131 6
111) lesions,5 which was per se a predictor for restenosis.
Of note, for the ultimate indication, the application of
DA is off-label use.5
Alternatively to DA, some multicenter experiences
exist with the rotational aspiration atherectomy device
(Jetstream; Pathway Medical Technology, Kirkland, Wash)in infrainguinal arteries, with acceptable long-term technical
and clinical data in de novo lesions.15 A substudy proved
the feasibility of the Jetstream device for in-stent restenosis,
with a success rate of 98% in an average lesion length of
8.6 cm16; however, follow-up data are not yet published.
So far, some evidence exists for drug-eluting technolo-
gies in the femoropopliteal artery, but the data are conﬂict-
ing. Two randomized trials with drug coating (everolimus
and sirolimus) on a self-expanding stent platform failed to
show superiority7,8 in de novo lesions. Promising data for
paclitaxel on a stent platform for de novo lesions were gener-
ated in the randomized Zilver PTX trial.9 Furthermore, the
Zilver PTX single-arm registry seems also to support the use
of the Zilver PTX stent (Cook Medical, Bloomington, Ind)
in femoropopliteal restenotic lesions.17 In the interim
12-month analysis, 120 instances of 818 treated target
lesions (15%) were available for the in-stent and 77 for rest-
enotic but not in-stent analysis. In-stent lesion length was
a little longer (12.66 8.9 cm) than nonein-stent restenotic
(10.4 6 8.3 cm) or de novo lesions (9.9 6 8.2 cm).
Freedom from target lesion revascularization, deﬁned as
clinically driven reintervention for >50% stenosis (peak
velocity ratio, 2.4), did not differ signiﬁcantly between
these groups, with 78% (93 of 120), 87% (67 of 77), and
91% (564 of 618), respectively.
However, DCB trials, such as the Thunder trial,
favored paclitaxel-coated DCB, reducing signiﬁcantly the
restenosis (15%) rate compared with PTA (52%) in native
and restenotic arteries, including in-stent restenosis,6 up
Fig. Probability of being free from restenosis is shown with the
95% conﬁdence interval (shaded area).
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nosis with paclitaxel DCBs did signiﬁcantly reduce late
lumen loss and the restenosis rate in the long term.10 Over-
all, paclitaxel seems to be effective for prevention of reste-
nosis in the femoropopliteal arteries. The underlying
mechanism is related to disruption of the microtubule
function, inhibiting smooth muscle cell migration and
proliferation and extracellular matrix secretion.18
Because the burden of intimaehyperplasia-associated
restenosis and in-stent restenosis in the peripheral arteries
is quite considerable, especially in long lesions, these data
support the approach of combining debulking with DCB,
thus avoiding additional stenting procedures.
Our study had several limitations. This was an observa-
tional study with a modest sample size and with non-
randomized groups, which may differ in observed and
unobserved characteristics resulting in differential selection
into treatment groups. The study was not powered for the
multitude of statistical tests we performed, thus some
signiﬁcant results could have occurred by chance alone.
CONCLUSIONS
This small study suggests for the ﬁrst time a beneﬁt of
adjunctive DCB angioplasty after DA for the treatment of
restenosis in native and stented lesions.
We thank the three anonymous reviewers and the
statistical reviewer for their comments.
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